Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals
Apellis Wins FDA Fast Track Designation for APL-2 in PNH
Jan. 4, 2017
Apellis Pharmaceuticals scored an FDA Fast Track designation for APL-2 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The candidate is intended for those who continue to experience hemolysis and require red blood cell transfusions, despite receiving therapy with eculizumab.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing